Immunohistochemistry Market Size, Share, Trends, Growth Outlook

Immunohistochemistry Market is estimated to increase at a Compounded Annual Growth Rate of 6.6% CAGR over the forecast period from 2024 to 2030

The Immunohistochemistry Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Antibodies, Reagents, Equipment, Kits), By Application (Diagnostic applications, Research applications, Forensic applications), By End-User (Hospitals, Diagnostic Laboratories, Research Institutes, Others).

An Introduction to Immunohistochemistry Market in 2024

Immunohistochemistry (IHC) is a laboratory technique used to visualize the distribution and localization of specific proteins or antigens within tissue samples using antibodies and detection methods. In 2024, immunohistochemistry remains a fundamental tool in research, pathology, and clinical diagnostics, providing valuable insights into the expression patterns and localization of proteins in tissues, organs, and tumors. In IHC, tissue sections are treated with specific antibodies that bind to target antigens of interest, followed by detection methods such as enzyme-linked immunosorbent assay (ELISA), fluorescence microscopy, or chromogenic reactions, which produce a visual signal indicating the presence of the target protein. Immunohistochemistry is widely used in cancer diagnostics to characterize tumor markers, subtype tumors, and guide treatment decisions based on the expression of specific biomarkers such as hormone receptors, growth factors, and cell surface antigens. Additionally, IHC plays a crucial role in research applications, including the study of protein localization, signaling pathways, and cellular interactions in normal and diseased tissues. With advancements in antibody technologies, multiplexing techniques, and digital image analysis, immunohistochemistry offers improved sensitivity, specificity, and throughput, allowing for more precise and quantitative analysis of protein expression patterns in tissue samples. Moreover, IHC-based assays can be integrated with other molecular diagnostic techniques, such as fluorescence in situ hybridization (FISH) or next-generation sequencing (NGS), to provide comprehensive molecular profiling of tumors and guide personalized treatment strategies in precision oncology. By enabling the visualization and characterization of protein expression in tissue samples, immunohistochemistry contributes to our understanding of disease pathogenesis, supports accurate diagnosis and prognosis, and facilitates the development of targeted therapies for cancer and other diseases.

Market Trend: Advancements in Cancer Diagnostics and Personalized Medicine

A significant trend in the immunohistochemistry (IHC) market is the continual advancements in cancer diagnostics and personalized medicine. Immunohistochemistry plays a crucial role in the diagnosis, prognosis, and treatment selection for various types of cancer by enabling the visualization and characterization of specific biomarkers and antigens in tissue samples. With the increasing understanding of the molecular mechanisms underlying cancer development and progression, there is a growing demand for IHC assays to identify biomarkers associated with specific cancer subtypes, tumor heterogeneity, and treatment response. Additionally, advancements in antibody technologies, imaging techniques, and digital pathology platforms are driving innovation in IHC methodologies, improving assay sensitivity, specificity, and multiplexing capabilities. As healthcare providers and researchers strive to tailor cancer treatments based on individual patient profiles and tumor characteristics, the demand for IHC assays as valuable tools for precision oncology and personalized medicine is expected to grow, driving market expansion and adoption of advanced IHC technologies.

Market Driver: Rising Incidence of Cancer and Demand for Biomarker-Based Diagnostics

A key driver fueling the immunohistochemistry (IHC) market is the rising incidence of cancer worldwide and the increasing demand for biomarker-based diagnostics. Cancer remains a leading cause of morbidity and mortality globally, with the incidence of various cancer types continuing to rise due to factors such as aging populations, lifestyle changes, and environmental exposures. Biomarker-based diagnostics, including IHC assays, play a critical role in cancer diagnosis, staging, and treatment decision-making by providing valuable information about tumor biology, molecular alterations, and therapeutic targets. IHC assays enable the detection and characterization of specific protein markers, hormone receptors, genetic mutations, and immune cell infiltrates in tumor tissues, guiding clinicians in selecting the most appropriate treatment modalities, such as targeted therapies, immunotherapies, or hormone-based therapies. As the importance of biomarker-driven cancer care grows and precision oncology approaches become standard practice, the demand for IHC assays for cancer diagnosis and patient management is expected to increase. Additionally, the development of companion diagnostics and predictive biomarkers further drives the adoption of IHC technologies in personalized cancer medicine, fueling market growth and investment in biomarker-based diagnostics.

Market Opportunity: Expansion into Companion Diagnostics and Predictive Biomarkers

A potential opportunity in the immunohistochemistry (IHC) market lies in the expansion into companion diagnostics and predictive biomarkers. Companion diagnostics are tests that are developed in conjunction with specific targeted therapies to identify patients who are most to benefit from treatment or to monitor treatment response. Predictive biomarkers, such as programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer, human epidermal growth factor receptor 2 (HER2) status in breast cancer, and microsatellite instability (MSI) in colorectal cancer, play a crucial role in guiding treatment decisions and optimizing patient outcomes. Immunohistochemistry is a valuable tool for assessing these biomarkers in tumor tissues, providing actionable information for personalized treatment selection and patient stratification. By expanding into companion diagnostics and predictive biomarkers, IHC providers can capitalize on the growing demand for biomarker-driven cancer care and participate in the development of precision oncology therapies. Additionally, there is an opportunity to collaborate with pharmaceutical companies, diagnostic laboratories, and healthcare providers to develop and validate IHC assays for companion diagnostic applications, driving market growth and differentiation in the competitive landscape. Expanding into companion diagnostics and predictive biomarkers presents a strategic opportunity for stakeholders to address unmet clinical needs, enhance patient care, and contribute to the advancement of personalized cancer medicine.

Immunohistochemistry Market Share Analysis: Primary Antibodies is the fastest growing segment over the forecast period to 2030

Among the segments of the Immunohistochemistry Market, Primary Antibodies emerge as the fastest-growing product category. This accelerated growth is driven by several factors. Primary antibodies are fundamental reagents in immunohistochemistry (IHC) assays, playing a crucial role in specifically binding to target antigens in tissue samples for detection and analysis. The increasing demand for primary antibodies stems from their pivotal role in diagnostic, research, and forensic applications, where precise and reliable antigen detection is essential. Moreover, advancements in antibody production technologies, such as monoclonal antibody development and recombinant antibody engineering, enhance the specificity, sensitivity, and reproducibility of primary antibodies, thereby expanding their utility in diverse immunohistochemical assays. Additionally, the growing prevalence of chronic diseases and cancer fuels the demand for IHC-based diagnostics in hospitals, diagnostic laboratories, and research institutes, further driving the adoption of primary antibodies. As healthcare providers and researchers prioritize accurate and efficient tissue analysis, the demand for high-quality primary antibodies continues to surge, propelling their rapid growth in the Immunohistochemistry Market.

Immunohistochemistry Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbcam plc, Agilent Technologies Inc, Becton, Dickinson and Company, Bio SB Inc, Bio-Rad Laboratories Inc, Bio-Techne Corp, Cell Signaling Technology Inc, Danaher Corp, Enzo Biochem Inc, F. Hoffmann-La Roche Ltd, Merck KGaA, Miltenyi Biotec, OriGene Technologies Inc, PerkinElmer Inc, PHC Holdings Corp, Sakura Finetek Japan Co. Ltd, Takara Bio Inc, Thermo Fisher Scientific Inc

Immunohistochemistry Market Segmentation

By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Immunohistochemistry Market Companies

Abcam plc
Agilent Technologies Inc
Becton, Dickinson and Company
Bio SB Inc
Bio-Rad Laboratories Inc
Bio-Techne Corp
Cell Signaling Technology Inc
Danaher Corp
Enzo Biochem Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Miltenyi Biotec
OriGene Technologies Inc
PerkinElmer Inc
PHC Holdings Corp
Sakura Finetek Japan Co. Ltd
Takara Bio Inc
Thermo Fisher Scientific Inc

Reasons to Buy the Immunohistochemistry Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Immunohistochemistry Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Immunohistochemistry Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Immunohistochemistry Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Immunohistochemistry Market Size Outlook, $ Million, 2021 to 2030
3.2 Immunohistochemistry Market Outlook by Type, $ Million, 2021 to 2030
3.3 Immunohistochemistry Market Outlook by Product, $ Million, 2021 to 2030
3.4 Immunohistochemistry Market Outlook by Application, $ Million, 2021 to 2030
3.5 Immunohistochemistry Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Immunohistochemistry Industry
4.2 Key Market Trends in Immunohistochemistry Industry
4.3 Potential Opportunities in Immunohistochemistry Industry
4.4 Key Challenges in Immunohistochemistry Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Immunohistochemistry Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Immunohistochemistry Market Outlook by Segments
7.1 Immunohistochemistry Market Outlook by Segments, $ Million, 2021- 2030
By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others

8 North America Immunohistochemistry Market Analysis and Outlook To 2030
8.1 Introduction to North America Immunohistochemistry Markets in 2024
8.2 North America Immunohistochemistry Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Immunohistochemistry Market size Outlook by Segments, 2021-2030
By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others

9 Europe Immunohistochemistry Market Analysis and Outlook To 2030
9.1 Introduction to Europe Immunohistochemistry Markets in 2024
9.2 Europe Immunohistochemistry Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Immunohistochemistry Market Size Outlook by Segments, 2021-2030
By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others

10 Asia Pacific Immunohistochemistry Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Immunohistochemistry Markets in 2024
10.2 Asia Pacific Immunohistochemistry Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Immunohistochemistry Market size Outlook by Segments, 2021-2030
By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others

11 South America Immunohistochemistry Market Analysis and Outlook To 2030
11.1 Introduction to South America Immunohistochemistry Markets in 2024
11.2 South America Immunohistochemistry Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Immunohistochemistry Market size Outlook by Segments, 2021-2030
By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others
12 Middle East and Africa Immunohistochemistry Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Immunohistochemistry Markets in 2024
12.2 Middle East and Africa Immunohistochemistry Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Immunohistochemistry Market size Outlook by Segments, 2021-2030
By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abcam plc
Agilent Technologies Inc
Becton, Dickinson and Company
Bio SB Inc
Bio-Rad Laboratories Inc
Bio-Techne Corp
Cell Signaling Technology Inc
Danaher Corp
Enzo Biochem Inc
F. Hoffmann-La Roche Ltd
Merck KGaA
Miltenyi Biotec
OriGene Technologies Inc
PerkinElmer Inc
PHC Holdings Corp
Sakura Finetek Japan Co. Ltd
Takara Bio Inc
Thermo Fisher Scientific Inc

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Antibodies
-Primary antibodies
-Secondary antibodies
Reagents
-Histological Stains
-Blocking Sera and Reagents
-Chromogenic Substrates
-Fixation Reagents
-Organic Solvents
-Proteolytic Enzymes
-Diluents
-Others
Equipment
-Slide-staining Systems
-Tissue Processing Systems
-Slide Scanners
-Others
Kits
-IHC Kits for Human tissue
-IHC Kits for Animal tissue
By Application
Diagnostic applications
Research applications
Forensic applications
By End-User
Hospitals
Diagnostic Laboratories
Research Institutes
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)